Bempedoic acid: less cardiovascular risk in hypercholesterolemia
This type of acid is the first oral ATP citrate lyase (ACL) inhibitor to reduce LDL cholesterol.
Bempedoic acid has been shown to reduce the risk of serious cardiovascular events in patients with hypercholesterolemia. Those who have a high risk of developing atherosclerotic cardiovascular disease. It is the first oral ATP citrate lyase (ACL) inhibitor to reduce LDL cholesterol (LDL-C) levels. There was a significant reduction in major adverse cardiovascular events in patients receiving bempedoic acid 180 mg/day. The lower a person’s LDL-C level, the lower their cardiovascular risk.
With 10,000 lives lost every day to cardiovascular disease in Europe, we are really encouraged by these new data showing that bempedoic acid does indeed reduce the risk of serious cardiovascular events for patients at high risk of heart attack or stroke. We look forward to sharing further analysis and insights and to work closely with the scientific and clinical communities to better understand how data can support the care of patients with cardiovascular disease across Europe.
Stefan Seyfried, Vice President Medical Affairs Specialty Medicines of Daiichi Sankyo Europe
To evaluate the treatment with bempedoic acid is CLEAR Outcomes. This is a randomized , event-driven, multicenter, double-blind, placebo-controlled Phase 3 study. The study included 14,014 patients at more than 1,200 sites in 32 countries. Patients were followed up for at least 36 months of follow-up.